InterMune (FRA:IUX) Net Margin % : -199.20% (As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is InterMune Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. InterMune's Net Income for the three months ended in Jun. 2014 was €-52.40 Mil. InterMune's Revenue for the three months ended in Jun. 2014 was €26.30 Mil. Therefore, InterMune's net margin for the quarter that ended in Jun. 2014 was -199.20%.

The historical rank and industry rank for InterMune's Net Margin % or its related term are showing as below:

FRA:IUX' s Net Margin % Range Over the Past 10 Years
Min: -2862.47 Med: -216.46 Max: 51.15
Current: -207.91

FRA:IUX's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -152.785 vs FRA:IUX: -207.91

InterMune Net Margin % Historical Data

The historical data trend for InterMune's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InterMune Net Margin % Chart

InterMune Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Net Margin %

Get a 7-Day Free Trial

-238.24

51.15

-2,862.69

-573.39

-312.16

InterMune Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Net Margin %	Get a 7-Day Free Trial															-436.60	-253.18	-221.49	-177.21	-199.20

Competitive Comparison of InterMune's Net Margin %

For the Biotechnology subindustry, InterMune's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InterMune's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's Net Margin % distribution charts can be found below:

* The bar in red indicates where InterMune's Net Margin % falls into.

InterMune Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

InterMune's Net Margin for the fiscal year that ended in Dec. 2013 is calculated as

Net Margin	=	Net Income (A: Dec. 2013 )	/	Revenue (A: Dec. 2013 )
	=	-160.285	/	51.347
	=	-312.16 %

InterMune's Net Margin for the quarter that ended in Jun. 2014 is calculated as

Net Margin	=	Net Income (Q: Jun. 2014 )	/	Revenue (Q: Jun. 2014 )
	=	-52.398	/	26.304
	=	-199.20 %

InterMune (FRA:IUX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

InterMune Net Margin % Related Terms

Thank you for viewing the detailed overview of InterMune's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

InterMune (FRA:IUX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.intermune.com

InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune (FRA:IUX) Headlines

No Headlines